Alzheimer's, Dementia & Mental Health
Game-Changing Find in Battle Against Alzheimer’s: A Gene Offers Protection
Study links cognitive decline in senior citizens with Alzheimer’s disease; says amyloid-beta plaque is cause of AD
July 12, 2012 - New research by deCODE Genetics is a game-changer in the battle against Alzheimer’s disease. It reveals a
gene that protects against Alzheimer’s disease (AD) and even cognitive decline in the elderly. The discovery also finds linkage between
age-related cognitive decline and late-onset forms of AD, the most common cause of dementia.
The gene that protects against AD is a variant of the amyloid precursor protein (APP) gene.
“APP was discovered 25 years ago in patients with rare, inherited forms of Alzheimer’s that strike in middle age,” writes
Ewen Callaway in a news report in the journal
Nature, which reported the research.
Obama Administration: A Plan To Prevent Alzheimer’s By 2025
Plan has been through months of
development since President Obama signed National Alzheimer’s Project Act
in January 2011, funding, however, an issue - see video - May 16, 2012
National Plan to Fight Alzheimer’s Presented by Obama Administration
HHS Secretary outlines research funding, tools for health care providers, awareness campaign and new website
May 15, 2012
Caregivers for Alzheimer’s Victims Find Yoga Improves Life, Slows Cellular Aging
Five million in U.S. care for people with dementia; stress puts them at high risk of depression
March 13, 2012
New Alzheimer’s Report Shows It Marches on as a Top Killer of America’s Seniors
Cost of AD to reach $200 billion this year – most for Medicare, Medicaid; 1 of 7 AD patients lives alone - see video
- March 8, 2012
War Against Alzheimer’s Gets Big Boost from Obama Administration Today
New research funds of $130 million, more for education, support of Alzheimer’s Project Act - Feb. 7, 2012
Large Numbers of Senior Citizens with Milder Alzheimer’s May See Diagnosis Change
New definition of ‘mild cognitive impairment’ changed; physicians may move AD patients back to MCI; seen more as
pre-Alzheimer’s - Feb. 6, 2012
Keeping Brain Active Protects Against Alzheimer’s But May
Be Too Late for Seniors
Study finds beta-amyloid causing protein not as common in those enjoying mental activities - Jan. 24, 2012
Alzheimer’s Association Gathers Ideas from 43,000 Americans to Help Develop U.S. Plan
Ideas in new report came from 43,000 people touched by the disease; 10 major challenges emerge - see video - Nov. 8, 2011
Read the latest news on
Alzheimer's, Dementia & Mental Health
“In the brain, APP is broken down into a smaller molecule called amyloid-β. Visible clumps, or plaques, of amyloid-β
found in the autopsied brains of patients are a hallmark of Alzheimer’s, but scientists have long debated whether the plaques are a cause of
the neurodegenerative condition or a consequence of other biochemical changes associated with the disease.
Callaway adds, “The latest finding supports other genetics studies blaming amyloid-β, and it makes the protein ‘the prime
therapeutic target’, says Rudolph Tanzi, a neurologist at the Massachusetts General Hospital in Boston and a member of one of the four teams
that discovered APP’s role in the 1980s.”
Alzheimer’s disease is a progressive neurodegenerative disease long associated with the production and accumulation of
beta-amyloid plaque. While several mutant forms of the APP gene have been linked to early-onset, aggressive forms of AD, there has been
limited evidence supporting a role for mutations in the gene in the more common late-onset form of the Alzheimer’s disease.
“Our results suggest that late-onset Alzheimer‘s disease may represent the extreme of more general age-related decline
in cognitive function,” said study lead author Kari Stefansson, M.D., Dr. Med., CEO of deCODE Genetics. “Also important, these data support
certain Alzheimer‘s disease drug development programs - some of which are already in human clinical trials.”
In searching for low-frequency variants of the APP gene associated with AD, deCODE scientists, together with their
colleagues from the pharmaceutical company Genentech, found a significant association with a mutation in whole genome sequence data from 1,795
people in Iceland.
The research team showed that the mutation is significantly more common in the study‘s elderly control group than in those
with AD, suggesting that the mutation protects against the disease. The researchers eventually studied the variant in nearly 400,000
The Genentech team then tested these findings and found a significantly reduced production of amyloid beta in cells.
“Our genetic data indicate that the mutation is protective against Alzheimer‘s disease,” said Stefansson.
“Our findings and the in vitro work done by Genentech also provide a proof of principle for the idea that blocking BACE1
cleavage of APP may protect against Alzheimer‘s, offering greater confidence to pharmaceutical companies with active BACE1 inhibitor drug
Gene Mutation Defends Against Alzheimer’s Disease: Key Finding
Rare genetic variant suggests a cause and treatment for cognitive decline; discovery
confirms the principal suspect that is responsible for Alzheimer’s
Ewen Callaway, Nature
July 12, 2012 - Almost 30 million people live with Alzheimer’s disease worldwide, a staggering
health-care burden that is expected to quadruple by 2050. Yet doctors can offer no effective treatment, and scientists have not been able
definitively to pin down the underlying mechanism of the disease.
Read more at Nature...
A study of a rare gene mutation that protects people against
This study “provides the strongest evidence yet that excessive levels of a normal brain substance, beta amyloid, are a
driving force in the disease — bolstering hopes that anti-amyloid drugs already under development might alter the disease’s course or even
prevent it,” according to an article in the
New York Times by Gina Kolata.
“So far, the drugs have not succeeded. But scientists not connected with the new study said it suggested that the drug
companies’ big bets on anti-amyloid treatments could yet pay off.”
Cognitive Decline in the Elderly
To study the association of the protective mutation with general cognitive decline, the research team examined the
frequency of the mutation in the original Icelandic control group of those cognitively intact at age 85. The team found an enrichment of the
mutation in this group, consistent with its protective effect against AD.
Extending this work further, the team investigated cognitive function using a seven-category test in carriers of the
mutation and non-carriers in the age range of 80 to 100 years old. The research team found a statistically significant difference between
carriers and non-carriers, with the carriers of the mutation having a score indicative of better-conserved cognition. After removing known AD
cases, the team again found that carriers had better cognitive function, suggesting that the mutation extends its protective effect to the
elderly in general.
"The implication of these data is that general cognitive decline and late-onset Alzheimer‘s disease share biological
pathways,” said Stefansson. “It also suggests that approaches to treating Alzheimer’s may have benefit to those elderly who do not carry the
protective mutation, and do not suffer from AD.”
Alzheimer’s disease, a progressive neurodegenerative disorder, is the most common form of dementia that affects four to
eight percent of the elderly population worldwide. The neuropathological features of AD are the presence of extracellular amyloid plaques and
intracellular neurofibrillary tangles in the hippocampus and cortical grey matter of the AD brain.
Age-specific prevalence of AD nearly doubles after age 65, leading to a prevalence of greater than 25 percent in those
over the age of 90.
Headquartered in Reykjavik, Iceland, deCODE genetics is a global leader in analyzing and understanding the
human genome. Using its unique expertise and population resources, deCODE has discovered genetic risk factors for dozens of common diseases
ranging from cardiovascular disease to cancer.
In order to most rapidly realize the value of genetics for human health, deCODE partners with life
sciences companies to accelerate their target discovery, validation, and prioritization efforts, yielding improved patient stratification for
clinical trials and essential companion diagnostics. In addition, through its CLIA- and CAP-certified laboratory, deCODE offers DNA-based
tests for gauging risk and empowering prevention of common diseases. deCODE also licenses its tests, intellectual property, and analytical
tools to partner organizations. deCODE’s corporate information can be found at www.decode.com with information about our genetic testing
services at www.decodehealth.com and www.decodeme.com.
Financial Relief for Volkswagen Diesel Owners
You may be eligible for money damages if you owned or leased one of these VW, Porsche or Audi vehicles.
In the major scandal of 2015, Volkswagen cheated you and the world. They rigged diesel emission controls so you, nor regulators, would know how much pollution their cars were adding to our environment.
They were caught and have reserved $7.3 billion to help "make it right" with victims.
If you owned or leased one of these vehicles, contact us now.
Janicek Law attorneys are actively pursuing these cases against VW. Do Not Wait...
Janicek Law Firm, PC
(Call toll free)
VW Jetta SportWagen (2009–2014)
VW Golf (2010-2015)
VW Golf SportWagen (2015)
VW Beetle (2012–2015)
VW Passat (2012-2015)
Audi A3 (2010-2015)
VW Touareg (2009–2016)
Porsche Cayenne (2015)
Audi A6, A7, A8, Q5 Quattro (2016)